LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Corcept Therapeutics Inc

Closed

SectorHealthcare

70.13 -1.48

Overview

Share price change

24h

Current

Min

69.73

Max

70.64

Key metrics

By Trading Economics

Income

-9.8M

21M

Sales

-25M

157M

P/E

Sector Avg

61.365

51.748

EPS

0.169

Profit margin

13.069

Employees

500

EBITDA

-22M

3.4M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+98.87% upside

Dividends

By Dow Jones

Next Earnings

28 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-229M

7.5B

Previous open

71.61

Previous close

70.13

Corcept Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jun 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380 Million

14 Jun 2025, 01:24 UTC

Acquisitions, Mergers, Takeovers

Nippon to Close U.S. Steel Deal After National-Security Pact With Trump -- 3rd Update

13 Jun 2025, 23:50 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 Jun 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 Jun 2025, 23:09 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 Jun 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 Jun 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Millicom to Acquire Telefonica Ecuador for $380M

13 Jun 2025, 22:04 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 Jun 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Outside Date Extended to July 3

13 Jun 2025, 21:35 UTC

Acquisitions, Mergers, Takeovers

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 Jun 2025, 21:34 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets Mexico Approval for Viterra Deal

13 Jun 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bunge Gets China Approval for Viterra Deal

13 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13 Jun 2025, 20:45 UTC

Acquisitions, Mergers, Takeovers

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 Jun 2025, 20:34 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 Jun 2025, 20:14 UTC

Acquisitions, Mergers, Takeovers

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 Jun 2025, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 Jun 2025, 19:12 UTC

Market Talk

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 Jun 2025, 19:04 UTC

Market Talk

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 Jun 2025, 18:54 UTC

Market Talk

Correction to Gold Settles Market Talk

13 Jun 2025, 18:01 UTC

Market Talk

Gold Settles at Record High -- Market Talk

13 Jun 2025, 17:40 UTC

Market Talk

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 Jun 2025, 17:21 UTC

Market Talk

Dollar Index, Commodities Rise -- Market Talk

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 Jun 2025, 17:02 UTC

Acquisitions, Mergers, Takeovers

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

Peer Comparison

Price change

Corcept Therapeutics Inc Forecast

Price Target

By TipRanks

98.87% upside

12 Months Forecast

Average 139.33 USD  98.87%

High 145 USD

Low 131 USD

Based on 4 Wall Street analysts offering 12 month price targets forCorcept Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.